@article{d099180813894a4db607ad0a8554a94b,
title = "Phase I Trial of Targeted Alpha-Particle Immunotherapy with Actinium-225 (225Ac)-Lintuzumab (Anti-CD33) and Low-Dose Cytarabine (LDAC) in Older Patients with Untreated Acute Myeloid Leukemia (AML)",
author = "Jurcic, \{Joseph G.\} and Farhad Ravandi and Pagel, \{John M.\} and Park, \{Jae H.\} and Smith, \{B. Douglas\} and Levy, \{Moshe Yair\} and Estey, \{Elihu H.\} and Perl, \{Alexander E.\} and Hagop Kantarjian and Dennis Earle and Dragan Cicic and Scheinberg, \{David A.\}",
note = "Background: The use of short-ranged (50-80 µm), high-energy (\textasciitilde{}100 keV/µm) α particle-emitting isotopes for radioimmunotherapy may result in more specific tumor cell kill and less damage to normal tissues than β-emitters. 225Ac-lintuzumab consists of a radiometal that emits four α-particles linked to an anti-CD33 antibody.",
year = "2015",
month = dec,
day = "3",
language = "American English",
volume = "126",
journal = "Blood",
}